Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Behav Res Ther. 2016 Feb 15;79:7–14. doi: 10.1016/j.brat.2016.02.001

Figure 1.

Figure 1

Raw mean PSS-I (PTSD Symptom Severity Interview) scores during treatment (weeks 1-24) and follow-up (weeks 38 and 52). Treatment conditions: naltrexone with PE (NAL+PE), placebo with PE (PLA+PE), naltrexone with no PE (NAL+NoPE), and placebo with no PE (PLA+NoPE). All participants also received BRENDA (supportive counseling).